- Esperion to Participate in Upcoming June Investor Conferences
- First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
- Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
- Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Esperion Reports First Quarter 2024 Financial Results
- Esperion to Participate in Upcoming May Investor Conferences
- Esperion to Report First Quarter 2024 Financial Results on May 7
- Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
- Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
More ▼
Key statistics
As of last trade, Esperion Therapeutics Inc (0ET:STU) traded at 1.98, 197.82% above the 52 week low of 0.666 set on Oct 26, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.98 |
---|---|
High | 1.98 |
Low | 1.98 |
Bid | 2.05 |
Offer | 2.09 |
Previous close | 1.92 |
Average volume | 0.00 |
---|---|
Shares outstanding | 189.46m |
Free float | 188.47m |
P/E (TTM) | -- |
Market cap | 409.23m USD |
EPS (TTM) | -1.00 USD |
Data delayed at least 15 minutes, as of Jun 04 2024.
More ▼